BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 19938416)

  • 21. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacotherapy of patients with (early) rheumatoid arthritis].
    Jacobs JW; Blaauw AA; Dijkmans BA; van Riel PL; Bijlsma JW
    Ned Tijdschr Geneeskd; 2000 Jan; 144(5):211-6. PubMed ID: 10682647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescription rheumatology practices among Mexican specialists.
    Goycochea-Robles MV; Arce-Salinas CA; Guzmán-Vázquez S; Cardiel-Ríos MH
    Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and management of early rheumatoid arthritis.
    Brown AN
    J S C Med Assoc; 2003 Oct; 99(10):296-302. PubMed ID: 14621660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.
    Nikolaisen C; Rekvig OP; Nossent HC
    Scand J Rheumatol; 2005; 34(4):269-76. PubMed ID: 16195159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Rituximab (MabThera)--a new biological medicine in rheumatoid arthritis therapy].
    Nemec P
    Vnitr Lek; 2007 Nov; 53(11):1199-210. PubMed ID: 18277630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early rheumatoid arthritis.
    Mitchell KL; Pisetsky DS
    Curr Opin Rheumatol; 2007 May; 19(3):278-83. PubMed ID: 17414956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Practice guideline 'Diagnosis and treatment of rheumatoid arthritis'].
    Schipper LG; Hoekstra M; Vliet Vlieland TP; Jansen TL; Lems WF; van Riel P;
    Ned Tijdschr Geneeskd; 2009; 153():A944. PubMed ID: 20051161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular disease in rheumatoid arthritis: disease and treatment interactions and their implications on treatment decisions.
    Sanders S; Geraci SA
    J Miss State Med Assoc; 2010 Mar; 51(3):75-80. PubMed ID: 20827876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular disease in rheumatoid arthritis: a step forward.
    Myasoedova E; Gabriel SE
    Curr Opin Rheumatol; 2010 May; 22(3):342-7. PubMed ID: 20164773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Disease modifying anti-rheumatic drugs(DMARDs)].
    Matsuda Y
    Nihon Rinsho; 1999 Feb; 57(2):439-44. PubMed ID: 10078020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives on rheumatoid arthritis for the orthopedic surgeon: overview of early diagnosis and the tumor necrosis factor antagonists.
    Keith MP
    Am J Orthop (Belle Mead NJ); 2011 Sep; 40(9):E193-5. PubMed ID: 22022685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J; Madej M
    Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.